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Stromal tumor-infiltrating lymphocytes (sTILs) are important prognostic and predictive biomarkers in triple-negative (TNBC) and
HER2-positive breast cancer. Incorporating sTILs into clinical practice necessitates reproducible assessment. Previously developed
standardized scoring guidelines have been widely embraced by the clinical and research communities. We evaluated sources of
variability in sTIL assessment by pathologists in three previous sTIL ring studies. We identify common challenges and evaluate
impact of discrepancies on outcome estimates in early TNBC using a newly-developed prognostic tool. Discordant sTIL assessment
is driven by heterogeneity in lymphocyte distribution. Additional factors include: technical slide-related issues; scoring outside the
tumor boundary; tumors with minimal assessable stroma; including lymphocytes associated with other structures; and including
other inflammatory cells. Small variations in sTIL assessment modestly alter risk estimation in early TNBC but have the potential to
affect treatment selection if cutpoints are employed. Scoring and averaging multiple areas, as well as use of reference images,
improve consistency of sTIL evaluation. Moreover, to assist in avoiding the pitfalls identified in this analysis, we developed an
educational resource available at www.tilsinbreastcancer.org/pitfalls.
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INTRODUCTION
Despite the complexity of the immune system and intricate
interplay between tumor and host antitumor immunity, detection
of stromal tumor-infiltrating lymphocytes (sTILs), as quantified by
visual assessment on routine hematoxylin and eosin (H&E)-stained
slides, has emerged as a robust prognostic and predictive
biomarker in triple-negative and HER2-positive breast cancer1–3.
Stromal TILs are defined as mononuclear host immune cells
(predominantly lymphocytes) present within the boundary of a
tumor that are located within the stroma between carcinoma cells
without directly contacting or infiltrating tumor cell nests. Stromal
TILs are reported as a percentage, which refers to the percentage
of stromal area occupied by mononuclear inflammatory cells over
the total stromal area within the tumor (i.e., not the percentage of
cells in the stroma that are lymphocytes). Intratumoral TILs (iTILs),
on the other hand, are defined as lymphocytes within nests of
carcinoma having cell-to-cell contact with no intervening stroma.
Initial studies of TILs in breast cancer evaluated stromal and
intratumoral lymphocytes separately and while both correlated
with outcome, sTILs were more prevalent, more variable in
amount and shown to be more reproducibly assessed4–7. As such,
recommendations for standardized assessment of TILs in breast
cancer by the International Immuno-Oncology Biomarker Working
Group (also referred to as TIL-Working Group, or TIL-WG in the
manuscript; www.tilsinbreastcancer.org) recommend assessing
sTILs whilst strictly adhering to the definition as outlined above8.
Stromal TILs are prognostic for disease-free and overall survival
in early triple-negative breast cancers treated with standard
anthracycline-based adjuvant chemotherapy4–6,9,10. High levels of
sTILs are associated with improved outcome and increased
response to neoadjuvant therapy in both triple-negative and
HER2-positive breast cancers7,11–14. Recently, experts at the 16th
St. Gallen International Breast Cancer Conference endorsed
routine reporting of sTILs in triple-negative breast cancer15.
Studies involving or evaluating prognosis should now include
the evaluation of sTILs.
The expanding role sTILs play in breast cancer research,
prognosis and increasingly patient management, is predicated
on accurate assessment of sTILs. The pivotal studies cementing
the prognostic and predictive role of sTILs have been performed
by visual assessment on H&E-stained slides according to published
recommendations8. In the future, advances in machine learning
may open the door to automated sTIL assessment16. Until that
point, however, the onus for accurate sTIL assessment falls upon
the pathologist.
Management of breast cancer is continually evolving. In
contrast to the excisional biopsies of previous decades, an initial
diagnosis of breast cancer is now routinely rendered on needle
biopsy specimens. These small biopsies are particularly susceptible
to influence of tumor heterogeneity, limited tumor sampling and
technical artifacts such as crushing. Studies assessing concordance
of TILs between core needle biopsies and matched surgical
specimens (lumpectomy or mastectomy) report higher average
TIL counts (4.4–8.6% higher) in the surgical specimens17,18. The
difference in TIL scores between biopsies and surgical specimens
was found to be reduced when the number of cores was
increased18, suggesting tumor heterogeneity as a contributing
factor. Not specifically addressed was the tissue reaction and
inflammatory infiltrate associated with the biopsy procedure itself.
No increase in TIL scores within the surgical specimens was seen
when surgery was performed within 4 days of the biopsy
procedure. Conversely, surgery performed more than 4 days post
biopsy was an independent factor correlating with higher TILs in
the surgical specimen17. This corresponds to the timing of chronic
inflammatory infiltrates in wound healing. It should be noted,
however, that in most contemporary practice settings the delay
between biopsy and surgery is several weeks and per the
recommended guidelines, areas of scarring should be excluded
from sTIL assessment. The inflammation associated with wound
#A full list of authors and their affiliations appears at the end of the paper.
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healing is physically limited closely to the healing area and does
not spread extensively into the tumor itself or surrounding stroma.
Thus the impact of the biopsy procedure on sTIL levels in the
surgical specimen is likely minimal.
Routine use of neoadjuvant therapy is increasingly common in
triple-negative and HER2-positive breast cancers. These trends
necessitate that sTIL assessment be performed on small biopsy
samples and, in the absence of complete pathological response,
on postneoadjuvant excision specimens without compromising
accuracy. High levels of sTILs in residual tumor post neoadjuvant
therapy is associated with improved outcome in TNBC19,20. As
neoadjuvant samples possess distinct challenges, separate
recommendations for assessing TILs in residual disease after
neoadjuvant therapy have been published21.
Breast cancers show wide variation in morphology, particularly
in tumor cellularity and amount of tumor stroma. Two tumors of
the same size may exhibit the same absolute numbers of stromal
lymphocytes but have a different percentage of sTILs due to the
stromal content as a proportion of tumor area. High-grade tumors
can show extensive central necrosis with only a thin rim of viable
tumor resulting in minimal assessable tumor stroma even in large
resection specimens. Other inflammatory cells are not infrequently
seen infiltrating tumor stroma, including neutrophils, eosinophils
and macrophages, resulting in a more cellular appearance and
rendering assessment of stromal TIL density more challenging.
Apoptotic cells can mimic lymphocytes. Poor fixation and
technical artifacts in cutting and staining are recognized to
compromise sTIL assessment. Ill-defined tumor borders and widely
separated nests of tumor result in variability in defining what
constitutes tumor stroma. Preexisting lymphocytic aggregates
surrounding normal ducts and lobules, vessels or ductal carci-
noma in situ (DCIS) can also confound assessment. Heterogeneity
in sTIL distribution both within the tumor and at the invasive front
versus the central tumor all contribute to variation in pathologist
sTIL assessment.
In an effort to identify the sources of variation in assessment of
sTILs, we analyzed data and images from three-ring studies
performed by TIL-WG pathologists specifically evaluating con-
cordance in sTIL evaluation in breast cancer22,23. Based on the
findings of this analysis we designed an educational resource
available via the International Immuno-Oncology Working Group
website at www.tilsinbreastcancer.org/pitfalls to assist patholo-
gists in avoiding the different types of pitfalls identified. In
addition, we evaluated the impact of sTIL discrepancy on outcome
estimation using the data of a pooled analysis of 9 phase III clinical
trials9.
RESULTS
Identification of cases demonstrating variability using ring studies
by the TIL-Working Group
Three-ring studies evaluating concordance of sTIL assessment in
breast cancer were analyzed (Fig. 1). In the first ring study, 32
pathologists evaluated 60 scanned breast cancer core biopsy
slides22. This international group of pathologists from 11 different
countries were all members of the TIL Working Group. Some had a
special interest or subspecialty training in breast pathology, while
Fig. 1 Study flow diagram. Raw data and original scanned images from 3 previously performed ring studies were evaluated (shaded Box 1).
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others were general surgical pathologists, illustrating the wide
applicability of the approach. The only instructions given to the
scoring pathologists were to read and use the TIL assessment
guidelines published by the TIL working group8. The second ring
study was an extension of the first study using a more formalized
approach. A subset of 28 of the original 32 pathologists
participated and scored 60 different scanned breast cancer core
biopsy slides. In this study, each pathologist identified and scored
at least three separate 1 mm2 regions on each slide, representing
the range of sTIL variability and averaged the results into a final
score. Additionally, reference images representing different sTIL
percentages were integrated into the evaluation process (Fig. 2)22.
The last ring study was performed by six TIL-WG pathologists who
independently scored 100 scanned whole section (excision
specimen) breast cancer cases23.
In total, results from 220 slides were included for statistical
analysis (60 each from ring studies 1 and 2, and 100 from ring
study 3). The standard deviation for sTIL scores for each slide is
shown in Fig. 3. When comparing across studies, ring study
2 shows the least variation in sTIL scores between pathologists. The
cases with the 10% greatest standard deviation were identified
(Fig. 3 red squares) and the original scanned slides of the cases
were reviewed to identify factors contributing to discordant sTIL
assessment in these cases. Additionally, in Ring Study 1, a single
outlier case in the low sTIL range was also evaluated (Fig. 3a black
triangle). From Ring Study 3, three additional cases showing large
standard deviation were also included in the scanned slide
assessment (Fig. 3c black triangles). Overall, a total of 26 original
scanned images were reviewed by ZK (ring studies 1 and 2) and RK
(ring study 3) from cases identified as particularly problematic (i.e.,
showing high variability) in sTIL assessment.
Analysis of scoring variance between pathologists
Table 1 shows the intraclass correlation coefficient (ICC) and
concordance rate among pathologists for each of the 3 studies.
The ICC is the proportion of total variance (in measurements
across patients and laboratories) that is attributable to the
biological variability among patients’ tumors, while 1 – ICC is
the proportion attributable to pathologist variability. The ICC has a
range from 0 to 1 with a score of 1 having the maximum
agreement. Concordance rates were evaluated comparing differ-
ent sTIL cutpoints: <1 vs ≥1%; <5 vs ≥5%; <10 vs ≥10%; <30 vs
≥30%; <75 vs ≥75% for each pathologist by comparing all pairs of
pathologists.
The ICC was highest in ring study 2 compared to the other
studies. Ring study 2 specifically sought to mitigate effects of sTIL
heterogeneity with assessment of 3 separate areas and intra-
pathologist scoring bias by necessitating use of standardized
percentage sTIL reference images.
Evaluation of sources of variability in the three-ring studies
The scanned images of the H&E-stained slides from the most
discordant cases in each of the 3 ring studies were evaluated to
Fig. 2 Reference images representing percent sTIL scores. Available at www.tilsinbreastcancer.org.
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identify the histological factors contributing to the variation in sTIL
assessment. In total 26 original scanned images were reviewed—7
from ring study 1, 6 from ring study 2 and 13 from ring study 3.
Often multiple factors were present in each slide.
Heterogeneity in sTIL distribution
Heterogeneity in sTIL distribution was identified as a major
contributing factor in all of the ring studies and as the most
prevalent challenge in ring studies 1 and 2 (Table 2; Fig. 4). Based
on review of the most variable cases, increased sTIL density at the
leading edge versus central tumor were contributing factors in
43%, 17% and 54% of cases in ring studies 1 through 3,
respectively (Fig. 4a); and marked heterogeneity of sTIL density
within the tumor was identified in 29% cases in ring study 1 only
(Fig. 4b). Whereas in ring studies 1 and 3 pathologists provided a
global sTIL assessment based simply on the published scoring
recommendations8, ring study 2 specifically addressed the issue of
sTIL heterogeneity by requiring separate scoring of at least 3
distinct areas of the tumor representing the range of sTIL density.
Additionally, matching the tumor area observed with reference
percent sTIL images were a necessary part of the evaluation. Our
analysis supports that scoring and averaging multiple areas aids in
providing a more consistent result between pathologists. One
issue not resolved by this technique is the scenario of a tumor
comprised of variably spaced apart clusters of epithelial cells with
a dense lymphocytic aggregate associated with each cluster of
epithelial nests but sparse infiltrate between the clusters (Fig. 4c).
This pattern was identified as a contributing factor in 29% of
highly discordant cases in ring study 1, 50% of discordant cases in
ring study 2 and no cases in ring study 3. There appears to be
Fig. 3 Standard deviation as a function of mean across all sTILs scores for each slide in 3 ring studies assessing concordance amongst
pathologists. a Ring study 1, 32 pathologists evaluated 60 scanned core biopsy specimens. b Ring study 2, 28 pathologists evaluated
60 scanned core biopsy specimens. c Ring study 3, 6 pathologists evaluated 100 scanned whole section specimens. 10% of cases in each study
showing the greatest variability in sTIL scores are shown as red squares. Black triangles identify additional cases identified for slide
assessment.
Table 1. Comparison of intraclass correlation coefficient and pair-wise
observer concordance rate for 3 ring studies.
Ring study 1 Ring study 2 Ring study 3
ICC 0.7 (0.62–0.78) 0.89 (0.85–0.92) 0.76 (0.69–0.83)
Concordance ratesa
TILs <1 vs ≥1% 0.94 (±0.08) 0.94 (±0.04) 0.91 (±0.06)
TILs <5 vs ≥5% 0.83 (±0.09) 0.89 (±0.05) 0.84 (±0.1)
TILs <10 vs ≥10% 0.77 (±0.08) 0.86 (±0.05) 0.79 (±0.06)
TILs <30 vs ≥30% 0.81 (±0.08) 0.93 (±0.03) 0.87 (±0.04)
TILs <75 vs ≥75% 0.90 (±0.06) 0.92 (±0.03) 0.94 (±0.03)
ICC intraclass correlation coefficient, TILs tumor-infiltrating lymphocytes.
aThe concordance of all pairs of pathologists was calculated for five
different TIL-groups. The values in the table are the sample mean and
sample standard deviation of these concordance rates for all pairs of
pathologists in each study.
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uncertainty amongst pathologists in this situation as to whether to
only include the stroma associated with—but not touching—
tumor epithelium (showing high sTIL density) or all stroma within
the tumor mass including stroma intervening between spaced
apart clusters of malignant epithelium (showing low sTIL density).
This uncertainty increases variability in sTIL assessment and would
be reduced by strict adherence to the definition of sTILs provided
in the introduction. All stroma within a single tumor is to be
included within the sTIL assessment. In this situation, both the
higher density areas in close proximity to tumor cells and the
lower density areas located between epithelial clusters should be
included. One notable exception is a tumor with a central
hyalinized scar, where the acellular scar tissue should be excluded
from sTIL assessment.
Technical factors
Technical factors were the next largest source of discordance
(Table 3; Fig. 5). Poor quality slides with histological artifacts, as
can be seen secondary to prolonged ischemic time, poor fixation,
issues during processing, embedding or microtomy were identi-
fied as a contributing factor for discordance in 85% of the most
discordant scanned slides from ring study 3 (Fig. 5a). In contrast,
this was not deemed a contributing factor in any of the cases from
ring studies 1 or 2. These results are highly skewed based on the
studies assessed. Ring study 3 used a subset of H&E slides from
NSABP-B31, an older completed trial evaluating benefit of
trastuzumab in early HER2-positive breast cancer, which started
accrual in February 2000 across multiple centers. These were
excision specimens undergoing local community tissue proces-
sing. Variable ischemic and fixation times subsequently affected
the integrity of stromal connective tissue which is critical in sTIL
assessment. Ring studies 1 and 2 used pretherapeutic core
biopsies from the neoadjuvant GeparSixto trial, which accrued
between August 2011 and December 2012. Fixation and ischemic
time are less likely to have been an issue in these samples, which
(i) as biopsy samples are immediately placed in formalin without
requirement for serial sectioning and can be processed in a timely
fashion and (ii) were procured at a time when the preanalytic
variables had become substantially better understood and new
recommendations widely adopted. Not to mention, H&E stains
fade with passage of time, which itself impacts the ability to
produce quality scanned images. In the current era, with
awareness and adoption of standardization and monitoring of
preanalytical and analytical variables, poor quality H&E slides
should no longer be acceptable. Nonetheless, challenges remain
and variations in practice can result in poorly processed speci-
mens that are likely to directly and negatively impact sTIL
assessment. Crush artifact, which is more commonly seen in core
Table 2. Pitfalls in sTIL assessment in breast cancer slides identified from cases showing the highest variation in 3 ring studies (RS)—heterogeneity of
lymphocyte distribution.
Pitfall Frequency seen Recommendation
Heterogeneity 15/26 (58%)
Increased sTILs at the leading edge compared to
central tumor (Fig. 4a)
RS1: 3/7 (43%)
RS2: 1/6 (17%)
RS3: 7/13 (54%)
Increased density of lymphocytes at the leading front should be
included as long as the lymphocytes are within the boundary of
the tumor. Scoring multiple areas and averaging the results can
help with heterogeneous tumors.
Marked hterogeneity in sTIL density within the
tumor (Fig. 4b)
RS1: 2/7 (29%)
RS2: 0
RS3: 0
All stroma within the boundary of a single tumor is included in
sTIL assessment. Scoring multiple distinct areas encompassing the
range of sTIL density and averaging the results can assist in
providing a more reproducible overall sTIL score.
Variably spaced apart clusters of cancer cells with a
dense tight lymphocytic infiltrate separated by
collagenous stroma with sparse infiltrate (Fig. 4c)
RS1: 2/7 (29%)
RS2: 3/6 (50%)
RS3: 0
All stroma within a single tumor is included within the sTIL
assessment. In this situation, both the higher density areas closely
associated with (but not touching) epithelial clusters and the lower
density areas located between epithelial clusters are included.
[The exception is a central hyalinized scar, which is excluded from
scoring.] Scoring multiple areas and averaging the results can help
with heterogeneous tumors.
RS1 Ring Study 1, RS2 Ring Study 2, RS3 Ring Study 3.
Fig. 4 Heterogeneity in sTIL distribution as a cause of variation in
sTIL assessment in breast cancer. Different examples of hetero-
geneity include a increased sTILs at the leading edge (blue arrow)
compared to the central tumor (yellow arrow); b marked hetero-
geneity in sTIL density within the tumor; and c variably spaced apart
clusters of cancer cells with a dense tight lymphocytic infiltrate
separated by collagenous stroma with sparse infiltrate.
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biopsy samples, was seen in 1 case overall in ring study 1 (14%)
(Fig. 5b).
Out-of-focus scans were identified in 1 case each in ring study 1
(14%) and ring study 2 (17%) (Fig. 5c). In clinical practice,
particularly as sTILs are poised to impact patient management, an
out-of-focus slide should be rescanned before scoring. Notably,
this highlights an obstacle to incorporation of whole slide imaging
in routine practice. Consistent focus quality remains an issue
requiring dedicated support staff for loading, scanning, reviewing
and rescanning if necessary24.
Including wrong area or cells
Variability in defining the tumor boundary and scoring stroma
outside of the tumor boundary appears to have been a
contributing factor for variation in 33% of highly discordant cases
in ring study 2 and 15% of cases in ring study 3 (Table 4; Fig. 6a).
The discordant cases also highlighted situations of including
lymphocytes associated with DCIS (2 cases ring study (RS)1, 1 case
RS2) (Fig. 6a), lymphocytes associated with a component of the
tumor showing features of an encapsulated papillary carcinoma (1
case RS1) (Fig. 6b), and lymphocytes associated with benign
terminal duct lobular units (1 case RS1) (Fig. 6d). Difficulty
distinguishing iTILs from sTILs factored into 2 cases (29%) in ring
study 1 and 1 case (17%) in ring study 2 (Fig. 7a). Also identified in
ring study 1 was 1 case (14%) with prominent stromal neutrophils
(Fig. 7b) and 1 case (14%) with stromal histiocytes (Fig. 7c). It is
important to assess slides at a sufficiently high power to be able to
differentiate between types of immune cells. Neutrophils,
eosinophils, basophils, and histiocytes/macrophages are all
excluded from sTIL assessment. Two independent cases in ring
study 1 demonstrated misinterpretation of apoptotic cells for
lymphocytes (Fig. 7d) and artefactual falling apart of tumor cell
nests along the edge of a core biopsy mimicking the discohesive
appearance of TILs (Fig. 7e). Both are previously noted examples of
histomorphologic challenges.
Limited stroma within tumor for evaluation
An added factor identified was the presence of minimal stroma in
the tumor for assessment (Table 5; Fig. 8a). This was identified as a
contributing factor in 46% of cases in ring study 3. In a variation, 1
case (14%) in ring study 1 showed extensive tumor necrosis with
decreased available stroma for assessment (Fig. 8b). Two cases
(15%) of mucinous tumors, each with minimal stroma to assess
were identified in ring study 3 (Fig. 8c).
Clinical significance of variability in sTIL assessment by
pathologists
The online triple-negative breast cancer (TNBC)-prognosis tool
(www.tilsinbreastcancer.org) that contains cumulative data of 9
phase III TNBC-trials9, was used to analyze the impact of variation
in sTIL assessments (using the sTIL-scores of this analysis) on
Table 3. Pitfalls in sTIL assessment in breast cancer slides identified from cases showing the highest variation in 3 ring studies (RS)—technical factors.
Pitfall Frequency seen Recommendation
Technical factors 13/26 (50%)
Poor quality slides / Histological artifacts secondary
to prolonged ischemic time, poor fixation or issues
during processing (Fig. 5a)
RS1: 0
RS2: 0
RS3: 11/13 (85%)
Thankfully, in the current era, with greater awareness and
monitoring of preanalytical and analytic variables, these sorts of
poor quality H&E slides should not be an issue. If presented with
such a case, only intact, morphologically assessable areas should
be included in sTIL score. If applicable, one can cut and stain an
additional section or select a different block for assessment.
Crush artifact (Fig. 5b) RS1: 1/7 (14%)
RS2: 0
RS3: 0
More commonly seen in biopsy samples, crush artifact can
compromise sTIL assessment. Areas of crushing should be
excluded from sTIL evaluation.
Out-of-focus scan (Fig. 5c) RS1: 1/7 (14%)
RS2: 1/6 (17%)
RS3: 0
As part of a study one may struggle with scoring an out-of-focus
scan. In clinical practice, however, particularly as sTILs are poised
to impact patient management, there is no good justification to
not rescan the slide. If this is not a possibility most computer
programs have some capability of image correction.
RS1 Ring Study 1, RS2 Ring Study 2, RS3 Ring Study 3.
Fig. 5 Technical factors as a cause of variation in sTIL assessment
in breast cancer. Examples of different technical factors include a a
poor quality slide as can be seen secondary to prolonged ischemic
time, poor fixation or issues during processing; b crush artifact; and
c out-of-focus scan.
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6
npj Breast Cancer (2020)    17 Published in partnership with the Breast Cancer Research Foundation
outcome. The impact on outcome of different sTIL levels is
represented in Fig. 9, showing a prototypical example of a 60-year-
old patient with a histological grade 3 triple-negative breast
carcinoma, measuring between 2 and 5 cm (pT2) and showing
30% sTILs. Assuming she is node negative, if a pathologist
properly quantifies the percentage of sTILs, the 5-years invasive
disease-free survival (iDFS) is estimated at 76%. If the pathologist
deviates down 10% in scoring sTILs (i.e., 20% sTILs), the 5-years
iDFS decreases to 73%. Conversely, if the pathologist deviates up
10% in scoring sTILs (i.e., 40% sTILs), the 5-years iDFS goes up to
79%. These differences are modest from a purely prognostic
viewpoint, although larger variations would lead to more
pronounced differences in outcome estimation. If cutpoints are
used to decide on therapy, on the other hand, variation in values
around the cut point (as reflected in the concordance rates in
Table 1 and Supplemental material) may impact clinical manage-
ment. Additional examples of outcome estimation as a function of
sTILs are provided in the Supplemental material.
A new resource for pathologists
To assist pathologists in avoiding the different types of pitfalls in
the assessment of sTILs identified in this analysis, we have
developed an educational tool available via the International
Immuno-Oncology Working Group website at www.
tilsinbreastcancer.org/pitfalls. Both conventional pictures of micro-
scopic slides and digitized whole slide images (WSIs) of biopsies
and surgical resection specimens of breast and other cancers are
available to illustrate the described pitfalls. At this point in time,
we have included several examples of each of the pitfalls. In the
future, we intend to add extra illustrative examples to make this
Table 4. Pitfalls in sTIL assessment in breast cancer slides identified from cases showing the highest variation in 3 ring studies (RS)—scoring wrong
area or cells.
Pitfall Frequency seen Recommendation
Scoring wrong area or cells 12/26 (46%)
Defining tumor boundary and scoring
outside of tumor (Fig. 6a)
RS1: 0
RS2: 2/6 (33%)
RS3: 2/13 (15%)
Do not include fibrous scars (image; yellow arrow) or lymphoid aggregates
(blue arrow) beyond the invasive front of the tumor.
Including lymphocytes surrounding
DCIS (Fig. 6b)
RS1: 2/7 (29%)
RS2: 1/6 (17%)
RS3: 0
Lymphocytes surrounding DCIS are excluded from assessment of sTILs.
Myoepithelial stains can be used if there is doubt as to whether a particular
focus is invasive or in situ.
Including lymphocytes associated with
encapsulated papillary carcinoma (Fig. 6c)
RS1: 1/7 (14%)
RS2: 0
RS3: 0
Only score sTILs associated with conventional invasive carcinoma. Similar to
DCIS, lymphocytes associated with encapsulated papillary carcinoma should
not be included in the sTIL assessment of the invasive component.
Including lymphocytes surrounding
benign glands (Fig. 6d)
RS1: 1/7 (14%)
RS2: 0
RS3: 0
Lymphocytes associated with benign lobules or ducts should be excluded from
sTIL counts when carcinoma surrounds benign structures. Similar lymphocytic
infiltrates outside of the tumor boundary can identify these as not tumor-
related.
Including intratumoral TILs (iTILS) (Fig. 7a) RS1: 2/7 (29%)
RS2: 1/6 (17%)
RS3: 0
Certain cases show dense lymphocytic infiltrates within the tumor epithelial
nests, sometimes obscuring the boundary between tumor cells and stroma. It
is important to be aware that intratumoral TILs are excluded from the
assessment, which only includes TILs within the intervening stroma. If
necessary, a cytokeratin stain may assist with defining tumor from stroma.
Including neutrophils (Fig. 7b) RS1: 1/7 (14%)
RS2: 0
RS3: 0
Only lymphocytes and plasma cells are included in sTIL evaluation.
Pathologists should assess slides at a sufficiently high power to be able to
differentiate between types of immune cells. Neutrophils, eosinophils,
basophils, and histiocytes/ macrophages are all excluded from sTIL assessment.
Including histiocytes (Fig. 7c) RS1: 1/7 (14%)
RS2: 0
RS3: 0
Only lymphocytes and plasma cells are included in sTIL evaluation.
Pathologists should assess slides at a sufficiently high power to be able to
differentiate between types of immune cells. Neutrophils, eosinophils,
basophils, and histiocytes/ macrophages are all excluded from sTIL counts.
Misinterpreting apoptotic cells as
lymphocytes (Fig. 7d)
RS1: 1/7 (14%)
RS2: 0
RS3: 0
At low power apoptotic cells can mimic lymphocytes. Pathologists should
assess slides at a sufficiently high power to differentiate this mimic.
Artifactual falling apart of cells mimicking
TILs Fig. 7e)
RS1: 1/7 (14%)
RS2: 0
RS3: 0
Artifactual falling apart of tumor cells is more common in biopsy specimens,
particularly along the edge. At low power discohesive tumor cells can mimic
lymphocytes. Pathologists should assess slides at a sufficiently high power to
differentiate this mimic.
RS1 Ring Study 1, RS2 Ring Study 2, RS3 Ring Study 3.
Box 1 Key Points
● Stromal TILs are mononuclear cells (predominantly lymphocytes) present
within the boundary of a tumor that are located within the stroma between
carcinoma cells without directly contacting the carcinoma cell nests.
● Heterogeneity in sTIL distribution is the main contributing factor to
variability in assessment.
● Two key factors improve consistency of sTIL results:
∘ Scoring multiple areas in heterogeneous tumors and averaging results.
∘ Use of reference images.
● Poor sample processing or fixation can increase histological artifacts and
compromise assessment of sTILs.
● Careful adherence to the definition and morphology of sTILs is required to
avoid scoring stromal areas outside of the tumor boundary and mistaken
classification of artifacts, mitotic bodies, etc as sTILs.
Z. Kos et al.
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collection a ‘living’ library and continuously evolving learning tool
for the pathology community. We invite the pathology community
to provide examples of challenging cases for TIL evaluation via the
website.
DISCUSSION
In the current study, we evaluated factors which serve to increase
the interobserver variability of manual sTILs assessment. The data
Fig. 6 Scoring the wrong area as a cause of variation in sTIL assessment in breast cancer. Scenarios where there may be challenges in
deciding which areas to score include a difficulty defining the tumor boundary (dashed line) and including fibrous scars (yellow arrow) or
lymphoid aggregates (blue arrow) beyond the invasive front; b including lymphocytes surrounding ductal carcinoma in situ (DCIS) which may
be difficult to distinguish from invasive carcinoma; c including lymphocytes associated with an encapsulated papillary carcinoma component
of a tumor; and d including lymphocytes surrounding benign glands. Shown is invasive carcinoma (yellow arrows) surrounding a benign
lobule with associated lymphocytes; adjacent benign lobules (blue arrows) show dense lymphoid aggregates identify the lymphocytic
infiltrate to be related to the entrapped lobule rather than the carcinoma.
Fig. 7 Scoring the wrong cells as a cause of variation in sTIL assessment in breast cancer. Examples where the wrong cells are scored
include a counting intratumoral TILs (iTILS); b counting neutrophils; c counting histiocytes; d misinterpreting apoptotic cells as lymphocytes;
and e artifactual falling apart of cells mimicking TILs.
Z. Kos et al.
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were analyzed as both continuous and categorical variables.
Despite the challenges pathologists face in scoring sTILs, the
reported prognostic and predictive value of sTILs remains
consistent across multiple datasets analyzed by independent
investigators9,25. On the individual patient level, however, we have
shown that discrepancies in sTILs scoring between pathologists
results in different individual outcome estimations, requiring
refinements in the paradigm to maximize benefit and
minimize risk.
Notable strengths of this study include the evaluation of both
core biopsy and excision specimens, which reflect the reality of
clinical practice in which sTIL assessment will be performed.
Analyzing the concordance rates across various cutpoints allows
us to inform regarding reproducibility to aid in educated cut point
selection for future trials. If a singular cutpoint is used, variation in
values around that cutpoint can result in misassignment. However,
in the setting of an understanding of the scoring error, the
cutpoint can be adjusted to a range such that below is X, above is
Y and between is indeterminate, and based on a strategy of risk
management the overall risk is mitigated. The extensive reference
images in this manuscript, as well as the online education resource
with further examples (www.tilsinbreastcancer.org/pitfalls), are a
valuable reference guide to the pathology community.
A limitation to consider is the poor quality of many of the slides
from the excision specimen sections in ring study 3 that were
identified as showing the highest discordance. This skewed the
evaluation towards technical factors, which are likely to be less of
an issue in contemporary clinical practice, but are of relevance in
retrospective analyses from older clinical trials. Nonetheless, if
presented with such a case in practice, only intact, morphologi-
cally assessable areas should be included in sTIL score. If
applicable, one could attempt recutting and staining a new slide
or selecting a different block for assessment. This information
further bolsters the demands for optimal tissue handling and
processing.
Among the sources of variability identified, the greatest
challenge appears to be dealing with heterogeneous distribution
of sTILs. This issue was partially mitigated in ring study 2 which
required assessment and averaging of at least 3 separate areas of
tumor. The areas were selected by the pathologist to reflect the
range of sTIL density and could be within a single core or across
separate cores depending on the case. One may postulate that the
increased experience of having participated in ring study 1
accounts for the greater concordance in ring study 2; however, the
pathologists in ring study 3 had participated in the previous two
ring studies and nonetheless showed lower ICC and concordance
rates than ring study 2. Ring study 3 was the only study using
whole sections compared to core biopsies in the other two
studies. One could consider that the increased area of tumor in an
excision specimen could lead to increased discordance26. In
reality, however, many of the core biopsy cases contained multiple
tissue cores per slide with multiple separate fragments of tumor,
which likely negated any benefit of smaller tumor area. Although
the recommendation to score multiple areas and average them in
the setting of a heterogeneous tumor is within the published
recommendation guidelines8, the software in ring study 2 made
Table 5. Pitfalls in sTIL assessment in breast cancer slides identified from cases showing the highest variation in 3 ring studies (RS)—limited tumor
stroma.
Pitfall Frequency seen Recommendation
Limited stroma within tumor for
evaluation
8/26 (31%)
Small volume of intratumoral stroma
present for evaluation (Fig. 8a)
RS1: 0
RS2: 0
RS3: 6/13 (46%)
Assessing % sTILs is difficult when the denominator is very small. Evaluation
should be restricted to areas where there is clear stroma. The leading edge
ought to provide at least some tumor stroma for assessment.
Large areas of necrosis (decreases
scorable stromal component) (Fig. 8b)
RS1: 1/7 (14%)
RS2: 0
RS3: 0
Necrosis and associated granulocytes are excluded from sTIL assessment. Some
tumors show extensive necrosis with only a thin rim of viable cells at the
periphery. Only lymphocytes associated with viable tumor should be included.
Even in highly necrotic tumor, there are typically at least some viable areas along
the invasive front.
Mucinous tumors (Fig. 8c) RS1: 0
RS2: 0
RS3: 2/13 (15%)
Lymphocytes generally are absent within extracellular mucin. Thin septa and
fibrous bands are often present providing a stromal component for assessment.
Stroma associated with any ‘no special type’ component should be included.
RS1 Ring Study 1, RS2 Ring Study 2, RS3 Ring Study 3.
Fig. 8 Limited stroma within tumors as a cause of variation in sTIL
assessment in breast cancer. Difficulties in sTIL assessment related
to stroma include a tumor with small volume of intratumoral stroma
present for evaluation; b large areas of necrosis which decrease
scorable stromal component; and c mucinous tumors.
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this a firm requirement. Similarly, use of reference % sTIL images is
recommended in the guideline but was a mandatory component
of ring study 2. We identified these two key recommendations
from the scoring guidelines as having a major impact on
consistency of results. These two relatively simple steps: scoring
multiple areas in heterogeneous tumors and always using
reference images (to minimize personal assessment bias to always
“score high” or “score low”)27 substantially improve concordance.
This re-enforces the central importance of adhering to recom-
mendations in the scoring guidelines. Once factors of hetero-
geneity are excluded, taking the time to evaluate slides at a
sufficiently high power to distinguish lymphocytes from other
immune cells as well as mimics can further improve concordance.
Being cognizant of lymphoid aggregates around benign ducts and
lobules, vessels and DCIS outside of the tumor will help identify
these as unrelated to the invasive carcinoma when present within
the tumor boundary where these lymphoid aggregates should be
excluded from sTIL assessment.
Demonstration of the reproducibility of sTILs scoring is essential
for widespread adoption. The importance of sTILs as a biomarker
is being increasingly recognized resulting in recommendations by
multiple respected groups. The 2019 St. Gallen Panel recom-
mended that sTILs be routinely characterized in TNBC for their
prognostic value8,15. As of yet, however, insufficient data exists to
recommend sTILs as a test to guide systemic treatment. In
addition, the latest iteration of the WHO Classification of Breast
Tumours also includes information on sTILs28.
Stromal TIL-assessment by pathologists is now recognized as an
analytically and clinically validated biomarker. There is Level 1B
evidence that high levels of sTILs are associated with improved
outcome and an enhanced response to neoadjuvant therapy in
triple-negative and HER2-positive breast cancers7,11–14,29, and are
prognostic for disease-free and overall survival in early triple-
negative breast cancers treated with standard anthracycline-based
adjuvant chemotherapy4,6,9. Clinical utility [likelihood of improved
outcomes from use of the biomarker test compared to not using
the test]30 remains to be defined. A recent retrospective study
demonstrated that patients with Stage I TNBC with >30% sTILs
had excellent survival outcomes (5-year overall survival rate of
98% [95%CI: 95% to 100%]) in the absence of chemotherapy31,
paving the way for future randomized trials of chemotherapy de-
escalation in early TNBC.
Clinical utility for sTILs is also likely to come from cancer
immunotherapy, a rapidly emerging field aimed at augmenting
the power of a patient’s own immune system to recognize and
destroy cancer cells. The immune system is able to impart
selective pressure on cancer cells resulting in immune-evading
clones. Stromal TILs can identify tumors amenable to immu-
notherapies targeting immunosuppression32. Checkpoint inhibi-
tors of programmed cell death protein 1 (PD-1) and programmed
death-ligand 1 (PD-L1) are promising therapeutic interventions,
however predicting tumor response to these agents remains
challenging33. There is increasing hesitation about the utility of
the current predictive biomarker PD-L1 expression by IHC. The
utility of PD-L1 IHC is undermined by the well-characterized
geographic and temporal heterogeneity and dynamic expression
on tumor or tumor-infiltrating immune cells34. Technical differ-
ences, variable expression and variation in screening thresholds
for PD-L1 expression across assays pose additional limitations.
Studies have shown that although pathologists can score PD-L1
on tumor cells with high concordance, even with training they are
not concordant in scoring PD-L1 on immune cells35–37. There are
emerging data that sTILs, as assessed by the consensus-method
defined by the TIL Working Group, are predictive for response to
checkpoint-inhibition in metastatic triple-negative and HER2-
positive breast cancer38,39. The response rate is linear with
increasing sTILs related to a higher response rate39. Further
investigations are ongoing.
As we look to the future, automated sTIL assessment holds the
promise of adding complementarity to the current pathological
evaluation of breast cancers. A heterogeneous pattern of
lymphocyte infiltration may be better addressed with computa-
tional pathology methods40,41. Further, there is some evidence
that the spatial distribution of TILs may provide additional
prognostic information42. One study reported improved prognosis
and response to chemotherapy in TNBC with a diffuse,
homogeneous lymphocyte distribution versus a heterogeneous
distribution43. This requires further evaluation. Lymphocytes are
particularly well-suited to image analysis, as it is easier to
recognize these small blue dark cells against a stromal
Fig. 9 Variation in outcome estimation based on stromal TIL assessment. Shown is the variation in estimated outcome based on sTIL
assessment for a 60-year-old patient with a histological grade 3 tumor, 2–5cm in size and receiving anthracycline+taxane based
chemotherapy. Presuming a true value for sTILs of 30%, changes in estimated 5-year iDFS for 5, 10, and 20% deviations (increase and decrease)
in sTIL assessments are represented with 95% confidence bands. (All calculations were performed using the online triple-negative breast
cancer (TNBC)-prognosis tool9 available at www.tilsinbreastcancer.org).
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background than, for example, to distinguishing malignant cells
from normal epithelium. There is a surge in the development of
machine learning methods for TIL assessment44. The histopatho-
logic diagnostic responsibility will continue to reside with the
pathologist. Image analysis and computation pathology, which are
proven to be faster and more reproducible, are adjuncts that aid
the pathologist but do not replace the function of histopathologic
interpretation. Until these tools are available, the well-educated
and well-trained pathologist is the best approach. Rigorous
training, evaluation and practice are well documented to result
in improved intra- and inter-pathologist reproducibility. It is hoped
that by highlighting the specific pitfalls in sTIL assessment in this
manuscript – the forewarned pathologist is the forearmed
pathologist. Ongoing efforts to ensure reliable and reproducible
reporting of sTILs are a key step in their smooth progression into
the routine clinical management of breast cancer.
METHODS
Identification of cases demonstrating variability using ring studies
by the TIL-Working Group
We identified 3 ring studies evaluating concordance of sTIL assessment in
breast cancer performed by TIL-WG pathologists, for which we could
obtain individual pathologist data and images22,23. The ring studies were
performed on clinical trials material. All participating patients gave written
informed consent to sample collection and the use of these samples for
translational biomarker research, as approved by the Ethics Commission of
the Charité Universitätsmedizin Berlin. All relevant ethical regulations have
been complied with for this study. In ring study 1, 32 pathologists
evaluated 60 scanned breast cancer core biopsy slides22. Scores were
missing for 5 slides; the missing values were replaced by the mean of the
31 remaining scores. Ring study 2 was an extension of the first study. A
subset of 28 of the original 32 pathologists participated and scored 60
different scanned breast cancer core biopsy slides22. Ring study 3 was
performed by six TIL-WG pathologists who independently scored
100 scanned whole slide breast cancer cases23. In total, 220 slides were
included. For each individual slide, the variability (standard deviation)
among pathologists was measured from individual sTILs scores. The slides
with the highest 10% standard deviation were identified for evaluation.
Statistical analysis of scoring variance between pathologists
The R software environment was used for statistical computing and
graphics (version 3.5.0). Scoring variance among pathologists was analyzed
using the Intraclass Correlation Coefficient (ICC). ICC estimates and their
95% confidence intervals were calculated based on individual-pathologist
rating (rather than average of pathologists), absolute-agreement (i.e., if
different pathologists assign the same score to the same patient), 2-way
random-effects model (i.e., both pathologists and patients are treated as
random samples from their respective populations)45. To compute ICC, we
used the “aov” function to fit the data with a two-way random effect
ANOVA model (readers and cases). We followed Fleiss and Shrout’s
method to approximate the ICC confidence intervals46. We created custom
code for the concordance analysis. Concordance rates for all pairs of
pathologists were calculated at several sTIL density cutpoints: <1 vs ≥1%;
<5 vs ≥5%; <10 vs ≥10%; <30 vs ≥30%; <75 vs ≥75%. Specifically, each
concordance was the percent agreement from the 2 × 2 table created from
each cutpoint and pair of readers. The analyses were performed and
confirmed independently by two separate groups (RE & SM; Gustave
Roussy) and (BDG & WC; FDA). Details of the concordance analysis are
presented in Supplementary Tables 1–3.
Evaluation of sources of variability in the three-ring studies
Slides for ring study 1 and 2 were Whole Slide Images (WSI) and were
viewed using a virtual microscope program (CognitionMaster Professional
Suite; VMscope GmbH). Each slide identified as showing the top 10%
discordance, as well as specifically chosen cases (1 outlier low sTIL case in
ring study 1 and 3 additional high discordance cases from ring study 3)
were examined in order to identify potential confounding factors for
routine sTIL assessment.
Clinical significance of variability in sTIL assessment by
pathologists
The impact of variation in sTILs on outcome estimation was evaluated
using the online triple-negative breast cancer (TNBC)-prognosis tool
(www.tilsinbreastcancer.org) that contains cumulative data of 9 phase
III TNBC-trials. The sTIL scores of this analysis were used as the ground
truth. Specifically, different patient profiles were defined based on
standard clinicopathological factors: age, tumor size, number of
positive nodes, tumor histological grade and treatment. For a specific
patient profile and a value of sTIL, the tool was used to calculate the 5-
year invasive disease-free survival (iDFS). The iDFS is defined as the
date of first invasive recurrence, or second primary or death from
any cause.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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